Search
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
All-encompassing meeting on ALL highly rated by participants
Almost 200 delegates from over 30 countries benefitted from stimulating and excellent discussions about Acute Lymphoblastic Leukemia (ALL) at the EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia on April 12-14, 2018 in…
Read moreHighlights from the SWG
EventsParticipation in the 19th European LeukemiaNet (ELN) SymposiumLocation and dateThis event was held in Mannheim, Germany, on April 18, 2023. Chairs
D. Hoelzer
S. Chiaretti
Topics
Blinatumomab Frontline HOVON Trial (A. Rijneveld, Netherlands). Inotuzumab ozogamicin in MRD+ ALL (G.
About us
The European Hematology Association (EHA): “Towards prevention, cure, and quality of life for all patients with blood disorders”.
Read moreChildcare services
EHA is pleased to offer complimentary professional childcare services for registered Congress participants’ children throughout the duration of the EHA2025 Congress.
Read moreBoard elections
Shape the future of EHA by taking part in our 2025 Board election. Nominations closed on February 9, 2025. The ballot will open on April 8, 2025.
Read more